Merck Balance Sheet Analysis From 2010 to 2024

MRK Stock

USD 125.23 0.14 0.11%

Most indicators from Merck's financial ratios are interrelated and interconnected. However, analyzing financial ratios indicators one by one will only give a small insight into Merck Company current financial condition. On the other hand, looking into the entire matrix of financial ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Merck Valuation and Merck Correlation analysis.

At this time, Merck's Sales General And Administrative To Revenue is quite stable compared to the past year. Enterprise Value Over EBITDA is expected to rise to 46.87 this year, although the value of Discontinued Operations will most likely fall to about 563.2 M.

Most indicators from Merck's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Merck Company current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Merck Valuation and Merck Correlation analysis.

	2021	2022	2023	2024 (projected)
Gross Profit	35.1B	41.9B	43.9B	46.1B
Total Revenue	48.7B	59.3B	59.9B	32.5B

Gross Profit Total Revenue

Merck fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Property Plant And Equipment Gross	Common Stock Total Equity	Short Term Investments
Total Assets		0.57	0.72	0.79	0.87	0.53	0.28	0.88	0.73	1.0	0.22	0.74	0.61	0.3	0.74	0.93	0.59	0.15	0.7	0.98	0.3	0.8	0.49	0.27	0.95	0.16
Short Long Term Debt Total	0.57		0.92	0.75	0.25	0.89	0.91	0.75	0.2	0.59	0.69	0.11	0.9	-0.27	0.95	0.58	0.95	-0.55	0.97	0.5	0.27	0.24	0.76	0.75	0.64	-0.24
Other Current Liab	0.72	0.92		0.85	0.42	0.81	0.78	0.9	0.35	0.74	0.57	0.31	0.84	-0.19	0.94	0.71	0.89	-0.46	0.96	0.67	0.3	0.4	0.82	0.64	0.77	-0.1
Total Current Liabilities	0.79	0.75	0.85		0.4	0.61	0.6	0.93	0.42	0.81	0.64	0.28	0.63	-0.25	0.77	0.86	0.68	-0.43	0.82	0.73	0.52	0.37	0.86	0.4	0.87	-0.17
Total Stockholder Equity	0.87	0.25	0.42	0.4		0.33	-0.07	0.59	0.79	0.84	-0.17	0.9	0.43	0.67	0.47	0.72	0.36	0.57	0.4	0.9	0.08	0.93	0.05	0.1	0.72	0.37
Property Plant And Equipment Net	0.53	0.89	0.81	0.61	0.33		0.74	0.65	0.33	0.53	0.7	0.13	0.98	-0.14	0.84	0.57	0.93	-0.36	0.87	0.5	0.15	0.39	0.62	0.89	0.53	-0.4
Net Debt	0.28	0.91	0.78	0.6	-0.07	0.74		0.57	-0.21	0.33	0.65	-0.22	0.75	-0.51	0.8	0.28	0.84	-0.73	0.83	0.18	0.11	-0.09	0.73	0.71	0.41	-0.2
Retained Earnings	0.88	0.75	0.9	0.93	0.59	0.65	0.57		0.48	0.89	0.49	0.45	0.69	-0.14	0.82	0.84	0.76	-0.31	0.83	0.84	0.26	0.5	0.8	0.48	0.9	0.01
Cash	0.73	0.2	0.35	0.42	0.79	0.33	-0.21	0.48		0.69	0.1	0.8	0.35	0.54	0.38	0.75	0.24	0.44	0.35	0.8	0.41	0.81	0.11	0.07	0.6	-0.08
Non Current Assets Total	1.0	0.59	0.74	0.81	0.84	0.53	0.33	0.89	0.69		0.25	0.69	0.62	0.26	0.76	0.92	0.6	0.11	0.72	0.96	0.3	0.79	0.53	0.28	0.95	0.13
Non Currrent Assets Other	0.22	0.69	0.57	0.64	-0.17	0.7	0.65	0.49	0.1	0.25		-0.34	0.62	-0.63	0.53	0.4	0.63	-0.72	0.61	0.16	0.36	-0.09	0.8	0.71	0.3	-0.76
Cash And Short Term Investments	0.74	0.11	0.31	0.28	0.9	0.13	-0.22	0.45	0.8	0.69	-0.34		0.21	0.74	0.34	0.63	0.17	0.61	0.28	0.83	0.2	0.79	-0.1	-0.16	0.62	0.52
Net Receivables	0.61	0.9	0.84	0.63	0.43	0.98	0.75	0.69	0.35	0.62	0.62	0.21		-0.04	0.9	0.62	0.93	-0.29	0.91	0.57	0.13	0.47	0.6	0.83	0.62	-0.28
Common Stock Shares Outstanding	0.3	-0.27	-0.19	-0.25	0.67	-0.14	-0.51	-0.14	0.54	0.26	-0.63	0.74	-0.04		-0.05	0.23	-0.2	0.92	-0.12	0.38	0.08	0.67	-0.61	-0.38	0.19	0.47
Non Current Liabilities Total	0.74	0.95	0.94	0.77	0.47	0.84	0.8	0.82	0.38	0.76	0.53	0.34	0.9	-0.05		0.71	0.9	-0.34	0.99	0.68	0.27	0.47	0.7	0.63	0.79	-0.1
Inventory	0.93	0.58	0.71	0.86	0.72	0.57	0.28	0.84	0.75	0.92	0.4	0.63	0.62	0.23	0.71		0.55	0.03	0.72	0.92	0.53	0.72	0.57	0.25	0.94	-0.05
Other Current Assets	0.59	0.95	0.89	0.68	0.36	0.93	0.84	0.76	0.24	0.6	0.63	0.17	0.93	-0.2	0.9	0.55		-0.43	0.92	0.54	0.13	0.34	0.69	0.86	0.59	-0.19
Other Stockholder Equity	0.15	-0.55	-0.46	-0.43	0.57	-0.36	-0.73	-0.31	0.44	0.11	-0.72	0.61	-0.29	0.92	-0.34	0.03	-0.43		-0.42	0.23	-0.12	0.57	-0.74	-0.48	-0.03	0.46
Total Liab	0.7	0.97	0.96	0.82	0.4	0.87	0.83	0.83	0.35	0.72	0.61	0.28	0.91	-0.12	0.99	0.72	0.92	-0.42		0.64	0.35	0.4	0.75	0.66	0.77	-0.17
Total Current Assets	0.98	0.5	0.67	0.73	0.9	0.5	0.18	0.84	0.8	0.96	0.16	0.83	0.57	0.38	0.68	0.92	0.54	0.23	0.64		0.31	0.82	0.4	0.22	0.91	0.21
Short Term Debt	0.3	0.27	0.3	0.52	0.08	0.15	0.11	0.26	0.41	0.3	0.36	0.2	0.13	0.08	0.27	0.53	0.13	-0.12	0.35	0.31		0.12	0.3	-0.16	0.41	-0.27
Intangible Assets	0.8	0.24	0.4	0.37	0.93	0.39	-0.09	0.5	0.81	0.79	-0.09	0.79	0.47	0.67	0.47	0.72	0.34	0.57	0.4	0.82	0.12		0.07	0.16	0.65	0.15
Accounts Payable	0.49	0.76	0.82	0.86	0.05	0.62	0.73	0.8	0.11	0.53	0.8	-0.1	0.6	-0.61	0.7	0.57	0.69	-0.74	0.75	0.4	0.3	0.07		0.57	0.58	-0.37
Property Plant And Equipment Gross	0.27	0.75	0.64	0.4	0.1	0.89	0.71	0.48	0.07	0.28	0.71	-0.16	0.83	-0.38	0.63	0.25	0.86	-0.48	0.66	0.22	-0.16	0.16	0.57		0.22	-0.48
Common Stock Total Equity	0.95	0.64	0.77	0.87	0.72	0.53	0.41	0.9	0.6	0.95	0.3	0.62	0.62	0.19	0.79	0.94	0.59	-0.03	0.77	0.91	0.41	0.65	0.58	0.22		0.14
Short Term Investments	0.16	-0.24	-0.1	-0.17	0.37	-0.4	-0.2	0.01	-0.08	0.13	-0.76	0.52	-0.28	0.47	-0.1	-0.05	-0.19	0.46	-0.17	0.21	-0.27	0.15	-0.37	-0.48	0.14

Click cells to compare fundamentals

Merck Account Relationship Matchups

Merck fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	84.4B	91.6B	105.7B	109.2B	106.7B	60.3B
Other Current Liab	14.9B	16.3B	16.9B	18.0B	15.5B	16.3B
Net Debt	16.7B	23.7B	25.0B	18.0B	29.4B	30.8B
Retained Earnings	46.6B	47.4B	53.7B	61.1B	53.9B	32.6B
Cash	9.7B	8.1B	8.1B	12.7B	6.9B	5.6B
Net Receivables	6.8B	7.9B	9.2B	9.5B	11.1B	11.6B
Inventory	6.0B	6.3B	6.0B	5.9B	6.4B	3.7B
Other Current Assets	4.3B	5.5B	7.0B	7.2B	7.6B	8.0B
Total Liab	58.4B	66.2B	67.4B	63.1B	69.0B	72.5B
Total Current Assets	27.5B	27.8B	30.3B	35.7B	32.2B	19.2B
Short Term Debt	3.6B	6.4B	2.4B	1.9B	1.7B	2.3B
Intangible Assets	14.2B	14.6B	22.9B	20.3B	18.0B	14.3B
Accounts Payable	3.7B	4.6B	4.6B	4.3B	3.9B	2.8B
Other Liab	12.7B	12.1B	11.7B	9.1B	10.5B	10.2B
Other Assets	5.3B	7.8B	9.4B	7.4B	8.5B	5.5B
Long Term Debt	22.7B	25.4B	30.7B	28.7B	33.7B	17.2B
Good Will	19.4B	20.2B	21.3B	21.2B	21.2B	12.3B
Treasury Stock	(56.0B)	(56.8B)	(57.1B)	(56.5B)	(57.5B)	(54.6B)
Net Tangible Assets	(7.7B)	(9.5B)	3.5B	4.5B	4.1B	4.5B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Merck Company is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merck Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merck Company Stock. Highlighted below are key reports to facilitate an investment decision about Merck Company Stock:

How To Invest In Merck

Details

Is Merck Stock a good investment?

Details

What is Merck's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Merck Valuation and Merck Correlation analysis.

You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Complementary Tools for Merck Stock analysis

When running Merck's price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.

	Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	AI Investment Finder Use AI to screen and filter profitable investment opportunities
	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments
	Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope

Is Merck's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.453

Dividend Share

2.92

Earnings Share

0.14

Revenue Per Share

23.695

Quarterly Revenue Growth

0.058

The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Merck Balance Sheet Analysis From 2010 to 2024

Merck fundamental ratios Correlations

Merck Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Merck fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Merck Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Total Assets
Total Liab	+ 0.99	Non Current Liabilities Total
Total Current Assets	+ 0.98	Total Assets
Net Receivables	+ 0.98	Property Plant And Equipment Net
Total Liab	+ 0.97	Short Long Term Debt Total
Total Liab	+ 0.96	Other Current Liab

Short Term Investments	- 0.76	Non Currrent Assets Other
Accounts Payable	- 0.74	Other Stockholder Equity
Other Stockholder Equity	- 0.73	Net Debt
Other Stockholder Equity	- 0.72	Non Currrent Assets Other
Common Stock Shares Outstanding	- 0.63	Non Currrent Assets Other
Accounts Payable	- 0.61	Common Stock Shares Outstanding